April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Topical Nonsteroidal Therapy for Central Serous Retinopathy
Author Affiliations & Notes
  • M. R. del Cid
    Ophthalmology, University of Texas Health Science Center, San Antonio, Texas
  • M. A. Singer
    Ophthalmology, Medical Center Ophthalmology Associates, San Antonio, Texas
  • D. J. Bell
    Ophthalmology, Medical Center Ophthalmology Associates, San Antonio, Texas
  • Footnotes
    Commercial Relationships  M.R. del Cid, None; M.A. Singer, Genentech, Regeneron, NeoVista, Macusight, Allergan, Alcon, Thrombogenics, F; Allergan, ISTA, Alcon, Genentech, C; D.J. Bell, Genentech, Regeneron, NeoVista, Macusight, Allergan, Alcon, Thrombogenics, F.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3311. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. R. del Cid, M. A. Singer, D. J. Bell; Topical Nonsteroidal Therapy for Central Serous Retinopathy. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3311.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine if topical nonsteroidal drops have a beneficial effect in treating central serous retinopathy.

Methods: : A retrospective chart review was performed to identify patients diagnosed with central serous retinopathy who were prescribed topical nonsteroidal medications. Visual acuity and Stratus OCT data was collected.

Results: : Twelve eyes of 11 patients were included for analysis. Median visual acuity at initial presentation was 20/40 (range 20/20 to 20/150), and mean central foveal thickness was 444 microns (range 157 to 924 microns). Subsequent follow up visits and duration of medication use varied from 1 to 12 months. All 11 patients had improvement in vision with a median visual acuity of 20/30 (range 20/20 to 20/40) as measured on final follow up. All patients also demonstrated an improvement in mean foveal thickness, averaging 157 microns (range 130 to 198 microns) as measured on final follow up. Six of the 11 patients had significant improvement of vision (median 20/40 on initial presentation improving to 20/30) and central macular thickness (average 378 microns on initial presentation improving to 208 microns) after only one month of therapy. No adverse events were reported with the use of either nepafeanac or bromfenac at a dose of three to four times a day

Conclusions: : Topical nonsteroidal medications were well tolerated and appeared to hasten visual recovery in central serous retinopathy. This therapeutic modality thus offers a potential treatment option for those with this disease. Prospective controlled trials are necessary on a larger scale to determine if therapy has an effect on rate of recurrence.

Keywords: retina • edema • imaging/image analysis: clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×